Lonza adds a commercial spray-drying facility in Bend, Oregon
New US pharmaceutical spray-drying capacity increases output for drug processing and manufacturing.
Source →The trace
How it reaches your house.
Starting from Lonza Group, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Lonza Group →supply upspray-dried pharmaceutical formulations
Lonza's Bend project directly expands commercial spray-drying capacity, increasing the availability of spray-dried pharmaceutical formulation services.
“Lonza plans to build a commercial-scale spray-drying facility at its Bend, Oregon, site, expanding its capacity to develop and manufacture spray-dried pharmaceutical formulations.”
95% confidenceCited →Hovione →Prices easeLonza's added commercial spray-drying capacity can pressure Hovione's CDMO volumes, which would slightly reduce Hovione's demand for Budesonide API as an input.
43% confidenceHop 2
Budesonide API →supply upLonza’s added spray-drying capacity should raise Budesonide API availability, easing a moderately important input constraint for inhaler manufacturing.
86% confidenceHop 3
Inhalers →supply upAdded commercial spray-drying capacity can raise output of inhaled API streams, improving Budesonide API availability for inhaler production.
58% confidence
Where it lands
What you buy, and what you own.
Goods you buy
Inhalers
Companies you may own
No named companies on this path.
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.